Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News

Rhythm Pharmaceuticals (RYTM) has seen a significant 5-year return, but its current valuation suggests it might be overpriced, particularly after recent positive news on IMCIVREE and RM-718. The stock trades at a much higher Price/Sales ratio (33.1x) compared to the biotech industry average (10.9x), indicating it's priced for substantial future growth and optimism. While regulatory progress and trial data are encouraging, execution risks related to adoption, reimbursement, and further approvals could challenge maintaining its premium valuation.